Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
vendredi, octobre 16
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Alaunos Therapeutics Inc
TCRT
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$2.18
0.11
5.31%
Dern. MÀJ: Oct 15, 7:59 PM
$2.85
0.78
37.68%
Get Report
Aperçu
Actualités
Prévisions de résultats
Données financières
Sentiment
Actionnariat
Comparer
Rapport sur les stocks
Privacy Manager
Alaunos Therapeutics Financials
Alaunos Therapeutics (TCRT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Alaunos Therapeutics Q2 EPS $(0.63) Up From $(0.71) YoY
Alaunos Therapeutics (NASDAQ:TCRT) reported quarterly losses of $(0.63) per share. This is a 11.27 percent increase over losses of $(0.71) per share from the same period last year.
Benzinga Newsdesk
Recap: Alaunos Therapeutics Q3 Earnings
Benzinga Insights
PRO
Alaunos Therapeutics Q3 EPS $(0.04), Same As Last Year
Alaunos Therapeutics (NASDAQ:TCRT) reported quarterly losses of $(0.04) per share. This is unchanged from the same period last year.
Benzinga Newsdesk
PRO
Alaunos Therapeutics Q2 EPS $(0.04), Inline
Alaunos Therapeutics (NASDAQ:TCRT) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 20 percent increase over losses of $(0.05) per share from the same period last year.
Benzinga Newsdesk
Earnings Scheduled For May 10, 2023
Companies Reporting Before The Bell • Nomad Foods (NYSE:NOMD) is projected to report quarterly earnings at $0.42 per share on revenue of $851.81 million.
Benzinga Insights
PRO
Alaunos Therapeutics Q1 EPS $(0.04), Inline
Alaunos Therapeutics (NASDAQ:TCRT) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 20 percent increase over losses of $(0.05) per share from the same period last year.
Benzinga Newsdesk
